Literature DB >> 7033385

Anti-f Met-Leu-Phe: similarities in fine specificity with the formyl peptide chemotaxis receptor of the neutrophil.

W A Marasco, H J Showell, R J Freer, E L Becker.   

Abstract

We have prepared antisera in both rabbits and rats against f Met-Leu-Phe conjugated to a variety of carrier proteins. Over 40 peptides with widely varying reactivity for the neutrophil formylpeptide receptor have been tested for their ability to bind to rabbit antibody raised against fMLP10-BSA. Structure-activity studies of peptides structurally related to f Met-Leu-Phe demonstrate that the N-formyl group is mandatory for maximum antibody binding activity. Methionine in position 1 and phenylalanine in position 3 are found to confer maximum binding activity. Stereoselectivity of the antibody-combining site also has been demonstrated. Comparison of the ability of the peptides to bind to the antibody receptor with their reactivity for the neutrophil has demonstrated a strong correlation in the rank order of reactivity of the numerous synthetic peptides: for the alpha NH2-acyl group, r = 0.94; for position 1, r = 0.90; for position 2, r = 0.97; and for position 3, r = 0.78. This strong correlation is seen across species lines with both rabbit and rat antibodies. Significant differences, however, in the specificity of the antibody and neutrophil receptors are seen at the carboxyl terminus of phenylalanine, and beyond the phenylalanine ring, r = 0.29. In addition, bacterial chemotactic factor-enriched butanol extracts from Escherichia coli culture filtrates can also bind to anti-f Met-Leu-Phe, affording additional evidence for the similarity in the structure of the bacterial chemotactic factor to the synthetic chemotactic peptides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7033385

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Rous-Whipple award lecture. The formylpeptide receptor of the neutrophil. A search and conserve operation.

Authors:  E L Becker
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

2.  The cored sponge model of in vivo leucocyte chemotaxis.

Authors:  D M Mellor; D B Myers; V S Chadwick
Journal:  Agents Actions       Date:  1986-08

3.  Spasmogenic activity of chemotactic N-formylated oligopeptides: identity of structure--function relationships for chemotactic and spasmogenic activities.

Authors:  W A Marasco; J C Fantone; P A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

Review 4.  Anti-idiotype and anti-hormone receptor antibodies.

Authors:  A D Strosberg
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression.

Authors:  W Zimmerli; B Seligmann; J I Gallin
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Epitope diversity of angiotensin II analysed with monoclonal antibodies.

Authors:  C Picard; P Ronco; P Moullier; J Yao; B Baudouin; M Geniteau Legendre; P Verroust
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

7.  Characterization of the rat neutrophil formyl peptide chemotaxis receptor.

Authors:  W A Marasco; J C Fantone; R J Freer; P A Ward
Journal:  Am J Pathol       Date:  1983-06       Impact factor: 4.307

8.  Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide.

Authors:  A E Postlethwaite; J M Seyer
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

9.  De novo chemoattractants form supramolecular hydrogels for immunomodulating neutrophils in vivo.

Authors:  Fan Zhao; Jingyu Li; Ning Zhou; Jiro Sakai; Yuan Gao; Junfeng Shi; Bronia Goldman; Hayley M Browdy; Hongbo R Luo; Bing Xu
Journal:  Bioconjug Chem       Date:  2014-11-25       Impact factor: 4.774

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.